Cologne, Germany, November 23, 2020 – Bayer and m.Doc are jointly developing a new digital solution to improve the medical care of patients with atrial fibrillation, particularly patient adherence. This will make “it’s my life” a digital companion throughout the entire treatment pathway.
Improving the care of patients with atrial fibrillation by increasing adherence to therapy – Bayer and digital healthcare pioneer m.Doc set out with this goal more than a year ago. Now, both partners are presenting the results to the public with their “it’s my life” solution, which is based on the proven m.Doc Smart Health Platform. “We are pleased to join forces with m.Doc in this exclusive pilot project to pave the way for new digital business models and optimized communication channels between patients and healthcare professionals,” says Dr. Gisbert Kleeff, Managing Director at Bayer Vital in Germany, about the collaboration.
The background to the joint development is the approximately two million patients in Germany alone who suffer from non-valvular atrial fibrillation. The disease can be treated with a procedure known as catheter ablation. However, the lack of adherence to treatment is a well-known problem. Around a quarter of patients fail to take their prescribed medication within a year of the operation. This significantly increases their risk of stroke.
“We want to address the problem of lack of adherence with the help of our joint platform, especially in the first three months after hospitalization. Patients receive online offers from their supervising physician in addition to direct contact,” said Dr. Markus Mundhenke, Director of Health Policy Scientific Affairs at Bayer Vital, adding that video consultations with physicians, targeted information in patient language and reminders via smartphone can help ensure therapy success.
This makes “it’s my life” a constant digital companion for patients with atrial fibrillation – especially during follow-up care, where patients can be closely monitored. The new platform from Bayer and m.Doc offers patients access to a wide range of simple, easy-to-understand information in words and pictures about the disease, treatment and medication. After all, an informed patient not only feels much better cared for, but can also make better decisions.
In the event of a possible hospital stay, Bayer and m.Doc then use digital questionnaires, for example, to ensure that not only the patients are well informed, but also that the hospital staff learn as much as possible from the patients – for example about behavioral patterns or the individual effect of medication – which ensures optimum care. After the hospital stay – aftercare is extensively supported digitally – there is then a regular health check, via which the attending physician can query the patient’s condition at a previously defined interval, for example via video consultation. The medication reminder is also intended to ensure that the prescribed medication is actually adhered to, thus minimizing the risk of stroke.
“With “it’s my life”, we have created another application option based on our m.Doc Smart Health Platform. The big advantage is that many of the functions have already been successfully used in everyday practice in clinics, rehabilitation facilities or doctors’ offices for a long time, so that patients with atrial fibrillation can now also benefit from our experience and know-how. Above all, we hope that the strong focus on medication adherence will enable us to significantly reduce the risk of stroke in patients,” says Admir Kulin, founder and CEO of m.Doc GmbH, about the addition to the platform family.
About m.Doc GmbH
Founded in 2016, m.Doc is a digital healthcare pioneer from Cologne, Germany, that provides numerous digital solutions for clinics, rehabilitation and care facilities, and medical practices based on its Smart Health Platform. The company is at the center of a strong and steadily growing partner network that paves the way for digital innovations in the healthcare system. With its solutions tailored to the needs of the industry, m.Doc makes efficient care possible and thus gives doctors, nurses and medical staff more time for what is important: the patient.
For more information, visit www.mdoc.one.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. With its products and services, the company aims to benefit people by helping to solve the fundamental challenges of a steadily growing and aging world population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainability and its brand stands for trust, reliability and quality worldwide. In fiscal 2019, the Group generated sales of €43.5 billion with around 104,000 employees. Investments amounted to 2.9 billion euros and research and development spending to 5.3 billion euros.
Further information can be found on the internet at www.bayer.de.
Press contact m.Doc
m.Doc GmbH | Ursulaplatz 1 | 50668 Cologne, Germany
Tel: +49 (0) 221 / 669 637 00